



Resource impact summary report

Resource impact

Published: 14 August 2024

www.nice.org.uk

Contents

Resource impact summary report 3

Resource impact summary report

NICE has recommended linzagolix as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age only if:

- it is intended to be used for longer-term treatment (normally for more than 6 months, not for people who need short-term treatment, for example, before planned surgery)
- it is used in the following dosing regimens:
 - with hormonal ABT: 200 mg once daily
 - without hormonal ABT: 200 mg once daily for 6 months followed by 100 mg once daily

The list price of linzagolix is £80 for a 28 pack of 100 mg or 200 mg tablets. The list price of relugolix is £72 for a 28 pack of 40 mg tablets.

The [resource impact template](#) includes population growth which will have an impact on the overall resource and capacity impact figures.

This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care providers.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

ISBN: 978-1-4731-6538-0